Therapeutic Drug Monitoring
Secukinumab (Cosentyx® , Verxant®)Antibody screening - Qualitative ELISA Kit
- SKU:
- HUMB00067
- Product Type:
- ELISA Kit
- ELISA Type:
- Biosimilar ELISA
- Biosimilar ELISA Type:
- Qualitative
- Applications:
- ELISA
- Reactivity:
- Human
- Analytes:
- Secukinumab (Cosentyx®/Verxant®)
- Research Area:
- Anti-Inflammatory
Description
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit (HUMB00067)
The Assay Genie Secukinumab ELISA has been developed for the qualitative determination of antibodies to Secukinumab in serum and plasma.
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Test Principle
Solid phase enzyme-linked immunosorbent assay (ELISA) based on the sandwich principle. Controls and samples (serum or plasma) are incubated in the microtiter plate coated with the drug secukinumab. After incubation, the wells are washed. Then, horse radish peroxidase (HRP) conjugated probe is added and binds to secukinumab antibodies captured by the drug secukinumab on the surface of the wells. Following incubation wells are washed and the bound enzymatic activity is detected by addition of chromogen-substrate. Finally, the reaction is terminated with an acidic stop solution. The colour developed is proportional to the amount of secukinumab antibodies in the sample or controls. The results can be evaluated with using cut-off value.
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Product Information
| Information | Description |
| Application | Antibody screening - Qualitative |
| Required Volume (µl) | 10 |
| Total Time (min) | 140 |
| Sample Typle | Serum, plasma |
| Number of Assays | 96 |
| Detection Limit (ng/mL) | +/= |
| Spike recovery (%) | - |
| Shelf Life (year) | 1 |
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit - General Information
Secukinumab is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor marketed by Novartis. IL-17 is a group of proinflammatory cytokines released by cells of the immune system and and exist in higher levels in many immune conditions associated with chronic inflammation. By targeting IL-17A, secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology and was approved by the United States Food and Drug Administration on January 21, 2015 to treat adults with moderate-to-severe plaque psoriasis.
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Contents
| Size | Kit Contents |
| 1x12x8 | Microtiter Plate Break apart strips. Microtiter plate with 12 rows each of 8 wells coated with reactant. |
| 1 mL (negative) 0,3 mL (positive) | Control Negative & Positive Ready to use. Contains human serum and stabilizer, <0,1% NaN3. |
| 1x12 mL | Assay buffer Ready to use. Blue coloured. Contains proteins, <0,1% NaN3. |
| 1x12 mL | Horse radish peroxidase conjugated probe. Ready to use. Red coloured. Contains HRP conjugated probe, stabilizer and preservatives. |
| 1x12 mL | TMB substrate solution. Ready to use. Contains 3,3′,5,5′- Tetramethylbenzidine (TMB). |
| 1x12mL | TMB stop solution. Ready to use. 1N HCl |
| 1x50mL | Wash buffer (20x). Prepared concentrated (20x) and should be diluted with the dilution rate given in the “Pretest setup instructions” before the test. Contains buffer with tween 20. |
| 2x1 | Adhesive Foil. For covering microtiter plate during incubation |
Secukinumab (Cosentyx® , Verxant®) Free drug ELISA Kit Protocol
| 1 | Pipette 100µl of Assay Buffer non-exceptionally into each of the wells to be used. |
| 2 | Pipette 10 µL of each Negative control, Positive control and samples into the respective wells of microtiter plate Wells A1: Negative control B1: Negative control C1: Positive control D1 and on: Samples |
| 3 | Cover the plate with adhesive foil. Briefly mix contents by gently shaking the plate. Incubate 60 minutes at room temperature (18-25°C) |
| 4 | Remove adhesive foil. Discard incubation solution. Wash plate three times each with 300 µL Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel |
| 5 | Pipette 100 µL Conjugate into each well |
| 6 | Cover the plate with adhesive foil. Incubate 60 minutes at room temperature (18-25°C) |
| 7 | Remove adhesive foil. Discard incubation solution. Wash plate three times each with 300 µL Wash Buffer. Remove excess solution by tapping the inverted plate on a paper towel |
| 8 | Pipette 100 µL Substrate into each well |
| 9 | Incubate 20 minutes without adhesive foil at room temperature (18-25°C) in the dark |
| 10 | Stop the substrate reaction by adding 100 µL Stop Solution into each well. Briefly mix contents by gently shaking the plate. Colour changes from blue to yellow. |
| 11 | Measure optical density with a photometer at OD 450nm with reference wavelength 650 nm (450/650 nm) within 30 minutes after pipetting the Stop Solution. |
Related Products
Secukinumab (Cosentyx® , Verxant®)Free drug ELISA Kit
Therapeutic Drug Monitoring
Daratumumab (Darzalex®)Antibody screening - Qualitative ELISA Kit
Therapeutic Drug Monitoring
Durvalumab (Imfinzi®)Antibody screening - Qualitative ELISA Kit
Therapeutic Drug Monitoring
Evolocumab (Repatha® )Antibody screening - Qualitative ELISA Kit
Therapeutic Drug Monitoring
Abatacept (Orencia®)Antibody screening - Qualitative ELISA Kit
Therapeutic Drug Monitoring